Studies

comparing treatment outcomes of

Studies

comparing treatment outcomes of DZNeP mw PEG IFN+RBV for HCV-4 with HCV-1 and 2/3 have been limited by the small sample size of the HCV-4 group. We aimed to compare SVR and predictors of SVR in HCV-4 versus HCV-1 and HCV-2/3 patients treated with PEG-IFN+RBV in a meta-analysis. Methods: We performed a comprehensive literature search in MEDLINE and EMBASE for ‘genotype 4′ in November 2013 and reviewed abstracts from 2012-2013 AASLD, APASL, DDW, and EASL. Inclusion criteria were original studies with ≥25 treatment-naïve HCV-4 patients with direct comparison arms with HCV-1, 2, and/or 3 patients, and all treated with PEG IFN+RBV. Exclusion criteria were co-infection with HIV, HBV, or other HCV genotypes. We used random-effects models to estimate effect sizes and Cochrane Q-test (p-value <0.05) and I2 statistic (>50%) to estimate level of heterogeneity. Results: We included 6 studies

(868 HCV-4, 12,033 HCV-1, and 7,194 HCV-2/3 patients) in the primary analysis. Overall SVR was 53% (CI: 43-62%) for HCV-4, 44% (CI: 40-47%) for HCV-1, and 73% (CI: 58-84%) for HCV-2/3 (Table 1). EVR rates were higher for HCV-4 [72% (CI: 64-81%)] compared to HCV-1, [59% (CI: 58-61%)]. SVR in those patients APO866 Sitaxentan with EVR were 75% (CI: 61-86%) in HCV-4 and 64% (CI: 46-79%) in HCV-1. SVR in patients who did not achieve EVR were 10% (CI: 6-17%) for HCV-4, 13% (CI: 12-15%) for HCV-1 and higher for HCV-2/3 at 23% (CI: 16-33%). Conclusions: Pooled SVR rates were lowest for HCV-1 (44%) then HCV-4 (53%) and highest for HCV-2/3 (73%). EVR was not a good stopping

rule for HCV-2/3 but excellent for HCV-1 and 4, so patients can seek alternative therapy early. However, approximately three-quarter of HCV-4 patients treated with PEG IFN+RBV achieved EVR and three-quarter of these patients also achieved SVR, making this a reasonable treatment option for HCV-4 patients. Treatment Response: HCV-4 compared to HCV-1 or HCV-2/3 Disclosures: Mindie H. Nguyen – Advisory Committees or Review Panels: Bristol-Myers Squibb, Bayer AG, Gilead, Novartis, Onyx; Consulting: Gilead Sciences, Inc.; Grant/Research Support: Gilead Sciences, Inc., Bristol-Myers Squibb, Novartis Pharmaceuticals, Roche Pharma AG, Idenix, Hologic, ISIS The following people have nothing to disclose: Brittany E. Yee, Derek Lin, Nghia H. Nguyen, Bing Zhang, Philip Vutien, Carrie R. Wong, Glen A.

Related posts:

  1. TNF-Alpha Signaling Pathway studies have not a thorough analysis
  2. ABT-492 are also several ongoing studies are underway
  3. 120 However, the treatment duration employed in this study (5 day
  4. In 56 effectiveness studies of CBT in anxiety disorders in natura
  5. They are recommended agents in these guidelines for the treatment
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>